High-Alert Medicines and Similar Names

Introduction

Two questions protect patients every time a medicine moves through a pharmacy:

1. How badly could a mistake with this medicine hurt someone?
2. How easily could someone pick, read or hear the wrong product?

These questions have different answers. A medicine can be dangerous when it is used wrongly even if its name is unique. A harmless product can have a name that is easy to confuse with another. When both risks apply to the same product, you need to be most careful.

This lesson teaches you to keep the two risks apart, to confirm a product by its full identity and not just its name, to use checks that actually catch the error you are worried about, and to pass the right facts to the pharmacist.

What you will be able to do

• Tell whether a risk comes from harm if an error happens (high-alert) or from confusion between products (look-alike/sound-alike), and recognize when both apply.
• Compare complete product identities (ingredient, strength, dosage form, route and, where relevant, concentration and device) when names or packages look similar.
• Explain what makes a second check independent, and which error a specific check can catch.
• Recognize the boundaries of specific products:
• For warfarin, connect its safeguards to the patient's current directions and to the other products the patient says they use.
• For insulin, recognize product-specific schedule, composition and device limits.
• Record and pass along the facts a pharmacist or prescriber needs, using your site's workflow, without making the clinical decision yourself.

Before you start

You need everyday reading and simple arithmetic. It helps to have worked through Read a medicine identity before learning a name, but every term this lesson relies on is defined here.

A note on authority: the PTCE content outline is an exam blueprint, not a law. This lesson describes safety principles and product facts. It does not set out what technicians may legally do. Your state's rules and your site's written procedures decide who performs which check. A federal source does not cancel a state requirement or a site policy.

Two separate risks: harm if wrong, and chance of a mix-up

High-alert medicines: the stakes are high

High-alert medicine in plain words: if an error happens with this medicine, the patient is more likely to be seriously harmed.

The label describes the consequence of an error. It does not say errors happen more often. AHRQ's patient-safety primer gives these examples of high-alert groups:

• anticoagulants (medicines that reduce blood clotting)
• insulins
• opioids
• chemotherapy medicines

That list is a set of examples, not a complete catalog.

Because the stakes are high, these medicines get extra layers of protection. Examples include standardized instructions, careful documentation and targeted double checks.

Look-alike/sound-alike (LASA): a mix-up is easier

LASA in plain words: the name or the package is similar enough to another product's that someone could select, read or hear the wrong one.

The label describes the likelihood of a mix-up. It says nothing about how harmful that mix-up would be.

One defense is Tall Man lettering. This means writing the different letters of two similar names in capitals so the eye lands on the difference. FDA's Name Differentiation Project lists recommended pairs, including:

• hydrALAZINE / hydrOXYzine
• glipiZIDE / glyBURIDE
• traZODone / traMADol
• predniSONE / prednisoLONE

Why the difference matters

The two labels answer different questions:

• High-alert asks: If this goes wrong, how bad is it?
• LASA asks: How easy is it to get the wrong one?

Being on FDA's Tall Man list tells you a name pair has been confused. It does not tell you that either drug is high-alert. Being high-alert does not mean the name is confusable.

When both apply, protect against both. For example, opioids are among AHRQ's high-alert examples, and HYDROmorphone, an opioid, appears on FDA's Tall Man list. A mix-up is more likely and more harmful.

Question 1

A coworker says, "hydrOXYzine is on the Tall Man list, so it must be a high-alert medicine." What is wrong with that reasoning?

Question 2

A pharmacy stocks an insulin whose name is unique on the shelf. No other product has a similar name or package. Does the unique name remove its high-alert status?

Compare the whole product identity, not just the name

The fields that make up an identity

A product's identity is more than its name. FDA's description of generic drugs shows which fields must match: a generic has the same active ingredient, strength, dosage form (tablet, liquid and so on) and route (by mouth, injection and so on) as the brand it copies.

Each field is a separate check:

• Active ingredient: the substance that does the medical work.
• Strength: how much of it is in each unit.
• Dosage form: the physical form, including how it releases the drug. FDA's official dosage-form list names "TABLET," "TABLET, EXTENDED RELEASE" and "TABLET, DELAYED RELEASE" as separate forms. Release design is part of the form, not a small detail.
• Route: how it enters the body.
• For some products, concentration and device also matter. You will see this with insulin.

Worked example: same ingredient, different product

This is a fictional case. Every fact you need is given here.

A prescription is written for Drug X 150 mg tablet, by mouth. On the shelf, two bottles sit side by side:

• Bottle 1: Drug X 150 mg tablet
• Bottle 2: Drug X 150 mg extended-release tablet

Work through the fields in order:

Bottle 2 is a different dosage form, so it is a different product. Only Bottle 1 matches.

The tempting mistake: "Same ingredient, same strength, so it's the same thing." A matching ingredient tells you what the drug is. It does not tell you how it is built to release. If you stop checking after two matching fields, you can miss the field that differs.

Change one fact. Suppose the prescription had said extended-release. Now Bottle 2 is the match and Bottle 1 is the wrong product. Nothing on the shelf moved; only the order changed. That is why you compare against the order, field by field, every time.

Tall Man lettering points to the difference but does not finish the check

Tall Man letters pull your eye to the part of the name that differs, such as glipiZIDE versus glyBURIDE. That catches a wrong-name pick.

It does not confirm the strength, form or route. A bottle can carry the correct Tall Man name and still be the wrong strength.

Appearance is a clue, not proof

FDA says generic versions may differ slightly from the brand in appearance, such as color. In general, a color difference by itself does not mean something is wrong. You will see one important product-specific exception, warfarin, later in this lesson.

Separating similar products on the shelf

The PTCE outline lists separating inventory as an error-prevention strategy. The reasoning is physical. If look-alike packages are not next to each other, a reach to the familiar spot is less likely to land on the wrong one.

Separation lowers the chance of a mix-up. It does not replace reading the label.

Question 3

An order is for prednisoLONE. The bottle in your hand says predniSONE, with the same strength and form. Which identity field fails, and what helped you notice?

Question 4

Two generic tablet bottles contain the same ingredient, strength and form, but the tablets are different colors. A coworker says one must be counterfeit. What does the FDA information you learned support?

Separate verification: a check that can actually catch the error

What makes a check independent

An independent double check means a second person evaluates the work from the original information, without leaning on the first person's conclusion.

The independence is what makes it work. If the second person only reads back what the first person wrote, any error passes straight through, because both people are relying on the same mistaken step.

AHRQ reports nursing research in which a true independent double check detected about 93% of errors. That only held when the second check really was independent. Because checks take time, AHRQ advises targeting them at the highest-risk medicines and processes.

That research comes from hospital nursing, not pharmacy dispensing. The principle carries over to pharmacy. The exact percentage does not automatically carry over.

Worked example: a check aimed at a specific error

The order: Novolin 70/30.

What happened: a technician pulls NovoLog Mix 70/30 by mistake. Both names begin "Novo" and both packages show "70/30."

A check that is not independent: the checker reads the prepared label and asks, "70/30, correct?" The answer is yes, so the error passes. The checker confirmed the number the first person chose. They never compared the product to the order.

An independent check: the checker reads the order, then reads the product in hand, field by field. The brand name and product type do not match the order, so the error is caught.

What the check targets matters. The specific risk here is selecting the wrong product among look-alikes. So the check must compare the physical product to the original order, not the label to itself.

Barcode scanning works the same way

A barcode scan compares the code on the product with what the order expects. It catches a wrong product only if you scan the package that will actually be dispensed.

Scanning a different unit, or overriding a mismatch without resolving it, defeats the check. AHRQ describes a hospital nursing study in which such workarounds were linked to about three times the risk of error.

Correct arithmetic is not proof of the right product

This is a fictional case.

A prescription calls for 1 tablet daily for 30 days. You calculate 30 tablets. The arithmetic is right. But if you counted those 30 tablets from the wrong strength's bottle, the patient still gets the wrong medicine.

Arithmetic checks the quantity. It does not check the identity. Each needs its own check.

Question 5

A pharmacist checks a filled prescription by comparing the printed vial label with the computer entry. Both say the same strength. The tablets inside came from the wrong strength's bottle. Why didn't the check catch this, and what would a check need to compare to catch it?

Warfarin: safeguards tied to current directions and reported exposure

What warfarin is and why it is high-alert

MedlinePlus describes warfarin as an anticoagulant, a medicine that lowers the blood's ability to clot. It is taken as a tablet by mouth. It can cause serious bleeding, which can be fatal.

The prescriber adjusts the dose using a regular blood test called the INR, and the dose may go up or down over time. MedlinePlus stresses that patients should understand any new dosing instructions.

So for warfarin, "what the patient took last month" may not be "what the patient should take now." The current directions are the ones that count.

Safeguard 1: tablet color matches strength

AHRQ explains that warfarin tablet colors are standardized by strength across all manufacturers. Patients are often advised that if the prescription did not change, the tablet color should not change either.

Compare that with the general rule you just learned. For most generics, a color change can be normal. For warfarin specifically, the color is tied to the strength. A product-specific safeguard can override a general expectation.

Worked example: "My pills look different"

This is a fictional case. A patient picks up a warfarin refill and says, "These are a different color than last time."

Case A: the prescription is unchanged. Same strength, same directions. Because warfarin color follows strength, a new color suggests the bottle may contain a different strength. This is a possible wrong-strength error.

Do not reassure the patient with "generics can look different." That is true for many drugs, but it is the wrong explanation here. Hold the fill and bring it to the pharmacist.

Case B: the prescriber recently changed the strength. Now a new color is expected. But the patient's surprise suggests they may not know their dose changed. That is still something to pass to the pharmacist, because making sure the patient understands new directions is a counseling matter.

The same observation, a color change, leads to two different meanings. The fact that decides between them is whether the current directions changed.

Safeguard 2: one warfarin product at a time

MedlinePlus warns against taking two or more medicines that contain warfarin at the same time. MedlinePlus lists the brand names Coumadin and Jantoven. That listing does not tell you which brands are currently sold.

Suppose a profile shows warfarin from your pharmacy and the patient mentions "Jantoven" from another prescriber. Same ingredient, different names: that is a possible duplication, so flag it. For more on duplication, see Duplication, interactions and contraindications.

Safeguard 3: what else the patient reports using

MedlinePlus asks warfarin patients to tell their doctor and pharmacist about all prescription and nonprescription medicines, vitamins, supplements and herbal products. It names several that may interact, including:

• aspirin
• NSAIDs such as ibuprofen and naproxen
• omeprazole and famotidine
• ginkgo, garlic, ginseng and St. John's wort, among others

What a "may interact" list does and does not prove

This is an evidence question, so read the source carefully:

• "May interact" means a possible interaction is recognized. It does not tell you, for each product, whether warfarin's effect would go up or down, or whether it matters for this patient.
• Sometimes the source does state a direction. MedlinePlus says cigarette smoking may decrease warfarin's effectiveness, and that some listed products may increase bleeding risk.
• For vitamin K–containing foods, MedlinePlus says only that they can affect how warfarin works, and advises consistent intake. That statement gives no direction.

Your job is to recognize that a reported product is relevant and pass it on. Deciding how much it matters is the pharmacist's job.

A symptom after a change does not prove the change caused it

A patient says, "I started ginkgo last week and now I bruise easily." The timing is worth reporting. It does not prove ginkgo caused the bruising. Other causes are possible, and only a clinical review can sort them out.

FDA notes that people can report a suspected problem even when they are not sure the drug caused it. Report what happened and when. Do not report a conclusion.

Warning signs are examples, not a checklist

MedlinePlus lists bleeding signs that call for contacting a doctor immediately, such as bleeding that won't stop, red or black stools, or vomiting material that looks like coffee grounds. That list is not complete. A patient who reports none of those signs has not been shown to be safe.

Any report of unusual bleeding, a fall, a head injury or another unusual problem goes to the pharmacist promptly, following your site's urgent-escalation steps. You recognize and route; you do not triage.

Question 6

A warfarin patient's prescription is unchanged. The patient says the tablets in today's refill are a different color. A new technician says, "Generic manufacturers change colors all the time; it's fine." What is wrong with that response, and what should happen?

Question 7

At the register, a patient who fills warfarin is buying naproxen. Which statement is best supported by MedlinePlus?

• A) Naproxen is guaranteed to make warfarin stronger in this patient.
• B) Naproxen is an NSAID that MedlinePlus lists as possibly interacting with warfarin, so the pharmacist should be involved before the patient relies on it.
• C) Naproxen has a different active ingredient, so there is no concern.
• D) The technician should suggest a different pain reliever.

Question 8

A patient says, "My new warfarin dose started Monday, and on Wednesday I had a nosebleed." Write the facts you would pass on. What conclusion should you avoid stating?

Insulin: boundaries that belong to specific products

Why insulin needs product-by-product attention

Insulin is high-alert (AHRQ). Insulin products also share a purpose, lowering blood sugar, which tempts people to treat them as interchangeable. They are not.

FDA's emergency insulin page states that switching insulin should happen under a doctor's care with close blood-sugar monitoring. Its emergency switching advice is for patients in disasters. It is not a substitution rule for pharmacy staff. Therapeutic substitution is on the PTCE outline's list of issues that require the pharmacist.

FDA's page separates insulins along three lines: when they are given, what they contain, and which devices they may be used with.

Schedule: when it is given

FDA's emergency page describes timing by insulin type. Those statements are written for patients in an emergency. They are not general dosing instructions, and they do not set the exact timing for every product in a group.

• Regular insulin (short-acting; for example, Humulin R and Novolin R): FDA's emergency page describes giving it further ahead of a meal than rapid-acting insulin.
• Rapid-acting insulin (for example, Apidra, Fiasp, Humalog, NovoLog): it starts working faster than regular insulin, so it is given closer to the meal. The exact timing differs by product. For example, the current Fiasp prescribing information says to inject it at the start of a meal or within 20 minutes after starting a meal. One rapid-acting product's timing does not tell you another's.
• Intermediate-acting insulin (for example, Humulin N and Novolin N) and long-acting insulin (for example, Lantus, Toujeo, Tresiba): FDA describes the long-acting examples as once-daily.
• Awiqli (insulin icodec): FDA describes it as once-weekly. It stays active for about a week, so its effect continues for days after a dose.

Both regular and rapid-acting insulin are used around meals, yet their timing differs. Sharing a purpose does not make two products interchangeable.

The timing that applies to a patient comes from the exact product's label and the prescriber's directions. You do not need to memorize minutes here. You need to recognize that timing belongs to the specific product, and to bring timing questions to the pharmacist.

Composition: what a mix contains

FDA's emergency page describes premixed insulins that combine two types in one product: an intermediate-acting insulin and a short- or rapid-acting insulin. For those mixes, FDA explains the numbers:

• The first number is the percentage of intermediate-acting insulin.
• The second number is the percentage of short- or rapid-acting insulin.

So for these products, 70/30 means 70% intermediate-acting and 30% short- or rapid-acting.

This reading applies to the intermediate-containing premixes FDA describes, such as Humulin 70/30, Novolin 70/30, Humalog Mix 75/25 and NovoLog Mix 70/30. Do not assume every insulin product with two numbers or the word "mix" follows the same pattern. Confirm the exact insulin ingredients on the product label.

Even within these mixes, the numbers do not say which short component is in the mix:

• Humulin 70/30 and Novolin 70/30 contain regular insulin.
• Humalog Mix 75/25 and NovoLog Mix 70/30 contain a rapid-acting insulin. FDA's emergency page says mixes with a rapid-acting component are injected closer to the start of the meal than mixes containing regular insulin.

Worked example: same numbers, different composition

Novolin 70/30 and NovoLog Mix 70/30 show the same numbers, and their names both begin "Novo." The 70/30 tells you the proportion. The product name tells you that the 30% is regular insulin in one and rapid-acting insulin in the other, which changes meal timing.

Change one fact. Compare Humalog Mix 75/25 with NovoLog Mix 70/30. Both mixes contain a rapid-acting component, but the proportions differ. Matching the short-component type does not fix a different ratio.

The lesson: "70/30" is one field of the identity, not the whole identity.

Device: where it may and may not be used

Device limits are often product-specific:

• Awiqli comes only as a prefilled pen. FDA says it must not be used in an insulin pump, mixed with other insulins, or drawn from the pen into a syringe.
• An insulin pump is a worn device that delivers insulin continuously. FDA says not all rapid-acting insulins are approved for pump use:
• Merilog is not currently labeled for pump use.
• Humalog U-200 and Lyumjev U-200 must not be used in pumps.
• FDA's page lists Humalog U-100 among products with pump-reservoir instructions.

So the U-number is part of the identity. The same brand name with a different U-number can have a different device boundary.

Labeling changes over time. The current label for the specific product is the authority, not a rule you assume applies to a whole class. For more on device details, see Product-specific respiratory and injection equipment.

Question 9

An order is for Humulin 70/30. The only 70/30 product within reach is NovoLog Mix 70/30. A coworker says, "Same ratio, same purpose. Use it." Using FDA's information, explain what differs and what should happen.

Question 10

A patient who uses an insulin pump brings in a prescription for Humalog U-200, and the profile notes pump use. What specific boundary does FDA's page give, and what do you do with that fact?

Pass the right facts forward

Who decides what

Your role is to recognize and record. The pharmacist or prescriber decides. The PTCE outline lists adverse drug events, therapeutic substitution, allergies, drug interactions and OTC recommendations among issues that require pharmacist intervention. For more, see Recognize when the pharmacist must intervene.

How you hand off is set by your site's written workflow, within your state's rules. That might be a hold queue, a note on the prescription, or a direct verbal alert for urgent issues.

What a useful handoff contains

A good handoff keeps the facts and leaves out guesses:

• the patient and the prescription involved
• what was ordered versus what you found (every identity field that differs)
• the patient's own words, and the timing of any change or symptom
• the source of each fact (profile, patient report, label)
• what you have done so far, such as "fill on hold"

Every item in the note must be something you actually verified, asked or did. If you did not ask about something, do not record an answer for it.

Worked example: rewriting a handoff note

This is a fictional case.

Weak note: "Pt on warfarin taking herbal stuff, probably causing bruising, told him it's fine."

The weak note has three problems:

• It is vague about the product.
• It states a cause the evidence does not show.
• It records advice the technician should not have given.

Now suppose these additional fictional facts are true. Each one was actually verified, asked or done before the note was written:

• Verified: the technician checked the profile and confirmed the current warfarin prescription on file has not changed since the last fill.
• Patient report: the patient said they started ginkgo about one week ago and said, "I bruise more easily now."
• Asked: the technician asked whether the patient uses any other prescription or nonprescription medicines, vitamins, supplements or herbal products. The patient said no others.
• Done: following the site's workflow, the technician placed the refill on hold for pharmacist review.

Useful note: "Warfarin patient (current Rx on file, unchanged). Patient reports starting ginkgo about 1 week ago and says, 'I bruise more easily now.' No other products mentioned when asked. Refill on hold pending pharmacist review."

The useful note keeps every fact, keeps the timeline, and leaves the judgment to the pharmacist. It contains nothing beyond the facts listed above.

If one of those facts were missing, the note would say less, not guess more. For example, if the technician had not asked about other products, the note should not say "no other products." It could say "other products not yet asked," or the technician could ask before writing. A note looks complete only because the work behind it was done.

If you later learn there was an error, Report errors and improve the system covers what happens next.

Question 11

What is the single biggest problem with this handoff: "Insulin pens look the same; gave her the Lantus instead of Toujeo, both are long-acting so no difference"?

Independent practice

These cases are new. Work each one before opening the answer.

Question 12

A prescription reads traMADol. The technician reaches for the bottle in the usual spot and sees "traZODone," same strength. Classify the risk(s) involved, and name one system safeguard from this lesson that targets this specific error.

Question 13

A coworker argues: "The PTCE outline lists bar code usage as an error-prevention strategy. So federal law requires every pharmacy to scan every fill, no matter what the state says." What is wrong with this conclusion?

Question 14

A prescriber writes for Drug Y 10 mg delayed-release tablets (fictional). Stock includes Drug Y 10 mg tablets and Drug Y 10 mg extended-release tablets, but no delayed-release product. A coworker suggests the extended-release version because "it's close." What do you do and why?

Question 15

A warfarin patient on an unchanged prescription mentions starting St. John's wort and says they feel fine. A coworker says, "No bleeding symptoms, so nothing to report." Evaluate that statement.

Question 16

Two insulin products are both described by FDA as rapid-acting. One is labeled U-200, and the patient's profile says they use a pump. A coworker says, "Rapid-acting is rapid-acting." Which identity field does the coworker ignore, and why does it matter here?

What to remember

• High-alert is about harm if an error happens. LASA is about how easily products get confused. Check for each risk separately; some products carry both.
• Confirm every identity field: ingredient, strength, dosage form (including release design) and route, plus concentration and device where they apply. Tall Man lettering points to differences; it does not finish the check.
• A second check helps only if it is independent and compares the real product to the original order. Correct arithmetic confirms quantity, not identity.
• Warfarin:
• Directions can change with INR results, so work from the current directions.
• Tablet color is standardized by strength, so an unexplained color change is a possible wrong strength.
• Two warfarin-containing products at once is a duplication.
• Reported OTC, herbal and supplement use matters. "May interact" does not tell you the direction, and a symptom after a change does not prove cause.
• Insulin:
• Schedule belongs to the specific product. Regular insulin is given further ahead of meals than rapid-acting insulin, but exact timing differs by product (Fiasp's label, for example, allows the start of a meal or within 20 minutes after starting), so follow the exact product label and the prescriber's directions. Some long-acting products are once-daily; Awiqli is once-weekly. FDA's emergency page is guidance for patients in emergencies, not a dosing rule.
• Composition: for the intermediate-containing premixes FDA describes, the first number is the intermediate-acting percentage and the second is the short- or rapid-acting percentage. The numbers do not say which short component is present, and not every product follows this pattern, so confirm the exact ingredients on the label.
• Device limits (pens, pumps, U-number) belong to specific products.
• A shared purpose does not authorize substitution.
• Recognize and record; the pharmacist decides. Pass on exact facts, the patient's words, timing and sources, through your site's workflow and within your state's rules. Record only what you actually verified, asked or did.

Review: A pen-only product has device restrictions

• Insulin: boundaries that belong to specific products

Review: Insulin switching is not a label-only substitution

• Insulin: boundaries that belong to specific products

Review: A weekly insulin is not a daily schedule with a new name

• Insulin: boundaries that belong to specific products

Review: Consistency is different from eliminating vitamin K

• Warfarin: safeguards tied to current directions and reported exposure

Review: A missed dose is not an arithmetic debt

• Warfarin: safeguards tied to current directions and reported exposure

Review: Stopping does not instantly remove an effect

• Warfarin: safeguards tied to current directions and reported exposure

Review: Warfarin checks connect the dose with the current plan

• Warfarin: safeguards tied to current directions and reported exposure

Review: Pause and predict

• Separate verification: a check that can actually catch the error